$29.92
+3.25
(+12.19%)▲
11.8%
Downside
Day's Volatility :12.0%
Upside
0.23%
77.41%
Downside
52 Weeks Volatility :80.89%
Upside
15.43%
Period | Scholar Rock Holding Corp | |
---|---|---|
3 Months | 222.76% | |
6 Months | 177.29% | |
1 Year | 154.86% | |
3 Years | 4.91% |
Market Capitalization | 2.5B |
Book Value | $0.99 |
Earnings Per Share (EPS) | -2.36 |
Wall Street Target Price | 39.875 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -67.1% |
Return On Equity TTM | -183.07% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -89.9M |
EBITDA | -228.5M |
Diluted Eps TTM | -2.36 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.47 |
EPS Estimate Next Year | -2.63 |
EPS Estimate Current Quarter | -0.6 |
EPS Estimate Next Quarter | -0.58 |
What analysts predicted
Upside of 33.27%
Sell
Neutral
Buy
Scholar Rock Holding Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Scholar Rock Holding Corp | 7.05% | 177.29% | 154.86% | 4.91% | 218.98% |
Regeneron Pharmaceuticals, Inc. | -21.61% | -24.74% | -7.55% | 13.66% | 101.19% |
Biontech Se | 1.94% | 14.27% | 14.47% | -63.37% | 445.2% |
Alnylam Pharmaceuticals, Inc. | -16.95% | 63.94% | 50.31% | 30.85% | 117.83% |
Vertex Pharmaceuticals Incorporated | -4.06% | 0.04% | 27.74% | 141.35% | 101.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Scholar Rock Holding Corp | NA | NA | NA | -2.47 | -1.83 | -0.67 | NA | 0.99 |
Regeneron Pharmaceuticals, Inc. | 18.41 | 18.41 | 1.11 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.04 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.18 | 0.53 | -0.03 | 0.12 | NA | 60.65 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Scholar Rock Holding Corp | Buy | $2.5B | 218.98% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.8B | 101.19% | 18.41 | 33.61% |
Biontech Se | Buy | $25.9B | 445.2% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $31.8B | 117.83% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $116.0B | 101.98% | 32.84 | -4.51% |
Artal Group S A
FMR Inc
T. Rowe Price Associates, Inc.
Samsara BioCapital, LLC
BlackRock Inc
Redmile Group, LLC
scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s
Organization | Scholar Rock Holding Corp |
Employees | 150 |
CEO | Dr. Jay Thomas Backstrom M.D., M.P.H. |
Industry | Health Technology |
Arc Document Solutions Inc
$29.92
+12.19%
Exscientia Plc
$29.92
+12.19%
Tmt Acquisition Corp
$29.92
+12.19%
Ngl Energy Partners Lp
$29.92
+12.19%
Ondas Holdings Inc
$29.92
+12.19%
Sonida Senior Living Inc.
$29.92
+12.19%
Vitesse Energy Inc.
$29.92
+12.19%
Spdr Marketaxess Investment Grade 400 Corp Bd Etf
$29.92
+12.19%
Blackrock High Yield Bond Etf
$29.92
+12.19%